🚀 VC round data is live in beta, check it out!
Pague Menos Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pague Menos and similar public comparables like Luyan Pharma, Genky Drug Stores, Shu Yu Civilian Pharmacy, Zjamp Group and more.
Pague Menos Overview
About Pague Menos
Empreendimentos Pague Menos SA operates a pharmacy chain in Brazil. It engaged in the retail trade of medicines, perfumes, personal hygiene, and beauty products. It revenues arises mainly from the sale of medicines, perfumes, and several self-service products to the end consumer.
Founded
1981
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$2B
Pague Menos Financials
Pague Menos reported last 12-month revenue of $3B and EBITDA of $194M.
In the same LTM period, Pague Menos generated $968M in gross profit, $194M in EBITDA, and $52M in net income.
Revenue (LTM)
Pague Menos P&L
In the most recent fiscal year, Pague Menos reported revenue of $3B and EBITDA of $229M.
Pague Menos expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $968M | XXX | $905M | XXX | XXX | XXX |
| Gross Margin | 33% | XXX | 32% | XXX | XXX | XXX |
| EBITDA | $194M | XXX | $229M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 8% | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $52M | XXX | $49M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | — | — | $294M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Pague Menos Stock Performance
Pague Menos has current market cap of $874M, and enterprise value of $2B.
Market Cap Evolution
Pague Menos' stock price is $1.32.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $874M | 0.0% | XXX | XXX | XXX | $0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPague Menos Valuation Multiples
Pague Menos trades at 0.5x EV/Revenue multiple, and 8.0x EV/EBITDA.
EV / Revenue (LTM)
Pague Menos Financial Valuation Multiples
As of March 9, 2026, Pague Menos has market cap of $874M and EV of $2B.
Equity research analysts estimate Pague Menos' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pague Menos has a P/E ratio of 16.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $874M | XXX | $874M | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | 8.0x | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBIT | 10.2x | XXX | 9.6x | XXX | XXX | XXX |
| EV/Gross Profit | 1.6x | XXX | 1.7x | XXX | XXX | XXX |
| P/E | 16.7x | XXX | 17.7x | XXX | XXX | XXX |
| EV/FCF | 122.8x | XXX | (531.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pague Menos Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Pague Menos Margins & Growth Rates
Pague Menos' revenue in the last 12 month grew by 13%.
Pague Menos' rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pague Menos' rule of X is 39% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Pague Menos Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | (2%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 39% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 23% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Pague Menos Public Comps
See public comps and valuation multiples for other Pharmacies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Luyan Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Genky Drug Stores | XXX | XXX | XXX | XXX | XXX | XXX |
| Shu Yu Civilian Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Zjamp Group | XXX | XXX | XXX | XXX | XXX | XXX |
| GoodRx | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pague Menos M&A Activity
Pague Menos acquired XXX companies to date.
Last acquisition by Pague Menos was on XXXXXXXX, XXXXX. Pague Menos acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Pague Menos
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPague Menos Investment Activity
Pague Menos invested in XXX companies to date.
Pague Menos made its latest investment on XXXXXXXX, XXXXX. Pague Menos invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Pague Menos
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pague Menos
| When was Pague Menos founded? | Pague Menos was founded in 1981. |
| Where is Pague Menos headquartered? | Pague Menos is headquartered in Brazil. |
| Is Pague Menos publicly listed? | Yes, Pague Menos is a public company listed on B3. |
| What is the stock symbol of Pague Menos? | Pague Menos trades under PGMN3 ticker. |
| When did Pague Menos go public? | Pague Menos went public in 2020. |
| Who are competitors of Pague Menos? | Pague Menos main competitors are Luyan Pharma, Genky Drug Stores, Shu Yu Civilian Pharmacy, Zjamp Group. |
| What is the current market cap of Pague Menos? | Pague Menos' current market cap is $874M. |
| What is the current revenue of Pague Menos? | Pague Menos' last 12 months revenue is $3B. |
| What is the current revenue growth of Pague Menos? | Pague Menos revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Pague Menos? | Current revenue multiple of Pague Menos is 0.5x. |
| Is Pague Menos profitable? | Yes, Pague Menos is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pague Menos? | Pague Menos' last 12 months EBITDA is $194M. |
| What is Pague Menos' EBITDA margin? | Pague Menos' last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Pague Menos? | Current EBITDA multiple of Pague Menos is 8.0x. |
| What is the current FCF of Pague Menos? | Pague Menos' last 12 months FCF is $13M. |
| What is Pague Menos' FCF margin? | Pague Menos' last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of Pague Menos? | Current FCF multiple of Pague Menos is 122.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.